/ /

Ophthalmology Times Staff Reports
ThromboGenics to develop protein therapies for diabetic eye disease
ThromboGenics NV has started research and development of innovative protein therapeutics to address a biologic target implicated in a range of diabetic eye diseases, such as diabetic macular edema.
AMD program generates eye disease awareness
Prevent Blindness America (PBA) along with its affiliates and partners is joining forces to promote a national “AMD: Awareness Makes a Difference” program to educate adults on the disease and the steps that can be taken, including regular eye exams, to protect their vision.
Transitions partners with ADA on eye health education
Transitions Optical Inc. continues to support the American Diabetes Association (ADA) by educating consumers about the importance of regular eye care for the early detection and treatment of diabetes during ADA Expo events.
Valeant to buy Bausch + Lomb for $8.7 billion
Valeant Pharmaceuticals International Inc. and Bausch + Lomb Holdings Inc. have entered into a definitive agreement, under which Valeant will acquire Bausch + Lomb.
Justine Smith begins term as new ARVO president
Justine Smith, FRANZCO, PhD, FARVO, of Flinders University, Adelaide, South Australia, is the new president of the Association for Research in Vision and Ophthalmology.
Most U.S. adults do not protect their eyes from UV radiation, report says
Despite the damaging effects of ultraviolet radiation (UV) to the eyes and vision, 40% of adults in the United States say they do not wear sunglasses while outdoors.
FDA approves B + L toric posterior chamber IOL
The FDA has approved Bausch + Lomb’s Trulign lens, a toric posterior chamber IOL that corrects for astigmatism and has the capacity to deliver improved vision across a natural range of focus.
Faces detected with retinal prosthesis
New data show that a retinal prosthesis system is capable of providing face detection functionality to blind individuals, said Paulo E. Stanga, MD.
Compound has potential in retinoblastoma
A new compound shows potential as a novel targeted therapy for retinoblastoma. While studies are still in the preliminary stages, the compound known as sd-rxRNA was able to penetrate all cell layers of the retina and was taken up by tumor cells within 24 hours of intravitreal administration, said Michael Byrne, PhD.
One-third of diabetics fail to get eye exams
An estimated 25 million people in the United States have diabetes and face a higher risk for ophthalmic complications, including glaucoma, cataracts, and diabetic retinopathy. However, more than one-third of all persons in the United States with diabetes did not undergo an eye exam in the past year, said Fang Ko, MD.


View Results